Editing CAR T cells to improve their functionality. Read our summary here => bit.ly/46yd31p  Univ. of Pennsylvania Department of Cancer Biology

Thank you Roland Schelker & Luca Gattinoni for this beautiful summary! Immunity cell.com/immunity/fullt……

New study in PNASNews from @CarlHJune, MD, Center Director for PICI Center Penn Medicine, and team reveals TP53 isoform Δ133p53α bolsters T cell fitness & reinvigorated CAR T cells from #CLL patients who previously didn't respond. pnas.org/doi/10.1073/pn… #immunotherapy #leukemia

Thank you Scientia for highlighting our work in this outreach article! Carl June #CARTcelltherapy

Twitter fam! We are looking for a research associate to join our awesome team. If you know anyone interested in the interface of protein engineering, structural bio, gene editing and T cell immunotherapy please reach out! Also, please retweet and spread the word!

Carl June and Michel Sadelain are the Qs who supplied a secret agent – the CAR T cell – with the technology to liquidate cancers. They will be honored at the Breakthrough Prize ceremony. Watch the worldwide premiere April 21 — streaming here and at youtube.com/watch?v=XnNsH2….

HHMI Foundation for the National Institutes of Health I am grateful and very honored for this recognition. Many thanks to my collaborators, trainees, and mentors for their wisdom and support.

Looking for the most effective ways to CRISPR edit human T cells? Look no further! Along with the team Penn we identified the engineering steps that control product function. Nearly 10 years of troubleshooting with Cas9 and novel base editors distilled down into 4 figures! (1/4)

A new NEJM Evidence study found racial disparities among patients treated with #CARTcelltherapy for #lymphoma. Penn Medicine - Abramson Cancer Center's Marco Ruella & Carmen Guerra are trying to find why these disparities exist to ensure all patients can benefit. The Philadelphia Inquirer spr.ly/60105Ydzm

Enhancing genome editing of T cells expressing synthetic antigen receptors ft. Nils_Wellhausen, Nils Engel, Caitlin Hopkins, January Salas-McKee, Adham Bear, Sangya Agarwal, Julie Jadlowsky, Gerald Linette, Saar Gill, Carl June, Joseph Fraietta & Nathan Singh tinyurl.com/3myvwyuj

Thank you for the warm welcome! I am beyond excited to join the DukeIntegrativeImmunobiology team at Duke University School of Medicine! Immensely grateful for the huge community of collaborators, mentors, friends and family whose support was integral to achieving this career milestone. Now the fun begins!

🎉 Congrats to HHMI Investigator Howard Chang of Stanford University, one of three 2024 Albany Prize winners recognized for breakthroughs in RNA science. Chang was honored for discovering long noncoding RNA and its role in the body’s response to infection. 👏 hhmi.news/47ZJQyj ✨

Very pleased to share our new online pre-print! We explore the spatial-temporal evolution of extrachromosomal DNA (ecDNA) in human glioblastoma. biorxiv.org/content/10.110…. A 🧵

Carl June awarded The Abarca Prize, says "Our journey is far from over, the fight against cancer is a marathon." Here congratulated by the King of Spain The Abarca Prize #celltherapy #genetherapy #immunotherapy

Today #CancerGrandChallenges team eDyNAmiC and their international collaborators published 3️⃣ papers in nature 📣 They show the prevalence of ecDNA in cancer, identify fundamental mechanisms and an actionable target now being tested in the clinic. More: bit.ly/4dUMU00

“Howard really models kindness that you want to see in a leader, and we all benefit from that.” – postdoc Roman Reggiardo on what it’s like working in Howard Chang’s lab at Stanford University

I am excited to join storied biotech pioneer Amgen 🧪🔬🧬 as Chief Scientific Officer and Head of Research. I look forward to partnering with my new colleagues to deepen understanding of biology and develop solutions to the most pressing medical challenges tinyurl.com/5n86sku5

A team at Penn, led by PICI Investigator Joseph Fraietta, PhD, including E. John Wherry, PhD, Co-Director of the PICI Center at Penn, & 2022 Parker Bridge Fellow Evan Weber, made a breakthrough in understanding TET2's role in T cell exhaustion: science.org/doi/10.1126/sc… (1/3)

Thrilled to share our new paper in Nature Medicine! We analyzed 783 patients (2,200+ patient-years) receiving lentiviral or gammaretroviral T cell therapies and found no evidence of high-level insertional mutagenesis. nature.com/articles/s4159…

Crystal Mackall and Carl June discussed groundbreaking strategies to enhance CAR T-cell therapies, pushing the boundaries for solid cancer treatment on day 3 of #AACRIO25. Learn more on the #AACRBlog: brnw.ch/21wR0gf Parker Institute for Cancer Immunotherapy Penn Medicine